Navigation Links
Women prescribed combination HRT should use caution when taking apigenin supplement, MU study finds
Date:11/20/2013

COLUMBIA, Mo. Hormone replacement therapies, or medications containing female hormones that substitute those no longer produced by the body, are often prescribed to reduce the effects of hot flashes and other menopausal symptoms in women. Research and clinical trials on hormone replacement therapies have indicated a higher incidence of tumors, especially breast cancer, in post-menopausal women who take synthetic hormones; therefore, doctors have become more reluctant to prescribe the treatment. In 2011, studies conducted by University of Missouri researchers found that a natural compound called apigenin, which is found in celery, parsley, and apples, could reduce the incidence of tumor growth in women receiving hormone replacement therapy. Now, based on subsequent studies conducted by MU researchers, they are recommending that women not ingest pure apigenin as a supplement.

A new study shows that when the supplement apigenin is ingested in a diet at the same concentration as subjects received during IV injections in previous studiesthe benefits were reversed leading to a higher incidence of cancerous tumors in subjects receiving progestin.

"Typically, hormone replacement therapies improve the lives of menopausal women and achieve very good results," said Salman Hyder, the Zalk Endowed Professor in Tumor Angiogenesis and professor of biomedical sciences in the College of Veterinary Medicine and the Dalton Cardiovascular Research Center. "However, research has proven that in women receiving therapies that involve a combination of the natural component estrogen and the synthetic progestin, a higher incidence of breast cancer tumors can occur."

Hyder explains that many women normally have benign lesions in breast tissue. These lesions don't typically form tumors until they receive the "trigger" that attracts blood vessels to cells essentially feeding the lesions causing them to form and expand in this case, progestin is the trigger. Hyder's previous research focused on identifying natural supplements containing compounds that lessen the likelihood of tumor development and growth.

During the study, laboratory rats were divided into four groups. Two groups were placed on a controlled diet; the other two were given apigenin through a diet supplemented with apigenin. Researchers found that the mice that ingested apigenin through their diets were found to have a higher incidence of tumor growth.

"We know that apigenin is effective when injected directly into the bloodstream, so intravenous supplements may still be a possibility," Hyder said. "However, the mice that ingested apigenin began metabolizing itwhich seemed to aggravate the situation causing very aggressive growth of mammary tumors."

"Women should continue consuming a healthy diet," Hyder said. "Fruits and vegetables most likely contain other protective compounds, and there is no data to suggest that these items are harmful. However, we do not recommend that women who are on hormone replacement therapy with a progestin component ingest pure apigenin as a supplement until further research proves otherwise. Until we know how apigenin is metabolized and interact with progestin effects, we cannot recommend that women supplement their hormone replacement therapy with this compound."

Researchers involved with the study included Benford Mafuvadze, post-doctoral fellow at Dalton Cardiovascular Research Center; Matthew Cook, pre-doctoral fellow in Biomedical Sciences; Cynthia Besch-Williford, professor of veterinary pathobiology; and Xu Zhang, visiting researcher at the Dalton Cardiovascular Research Center.

The research was recently published online in the journal Nutrition and Cancer.


'/>"/>

Contact: Jeff Sossamon
sossamonj@missouri.edu
573-882-3346
University of Missouri-Columbia
Source:Eurekalert  

Related biology news :

1. Women & Infants earns $3 million grant from National Institutes of Health
2. 3 hands on nutrition classes -- Enough to impact health behaviors in lower income women
3. Knowledge about incontinence and pelvic organ prolapse lower among women of color
4. Biological therapy with cediranib improves survival in women with recurrent ovarian cancer
5. Why wont she leave him? Abused women often fear for pets left behind
6. Flame retardant ban reduces exposures in pregnant women
7. Education protects women from the obesity associated with urban living
8. Vigorous physical activity linked to lower incidence of obesity in young African-American women
9. Calcium plus vitamin D supplementation does not reduce joint symptoms in postmenopausal women
10. Cultural mythologies strongly influence womens expectations about being pregnant
11. Women in urban areas show high rates of postpartum depression, study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Women prescribed combination HRT should use caution when taking apigenin supplement, MU study finds
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: